Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 339

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 339
---
 regenerative medicine company whose primary asset is an exclusive worldwide license from Johns Hopkins University (“JHU”)
for a biomatrix technology designed for soft tissue reconstruction. Aegeria is currently focused on using this technology in the treatment
of soft tissue aesthetic and lumpectomy defects. Clinical development of our technology has been primarily funded by a 2015 grant to JHU
from the Armed Services Institute for Regenerative Medicine and a 2020 grant to JHU from the U.S. Army Medical Research Acquisition Activity.

Cerevast Medical, Inc.

Cerevast is a
clinical-stage medical device company focused on the development of novel therapeutic solutions to restore health and improve the quality
of life for patients that suffer from major diseases by leveraging our core expertise in the fields of ultrasound and microsphere technologies.
Cerevast’s lead clinical stage programs are designed for the treatment of ischemic stroke and retinal vein occlusion, two devastating
diseases with limited treatment options that affect millions of patients worldwide each year.

Our Product Candidates and Pipeline

The following
table sets forth the consolidated development status of our current therapeutic product candidates and future pipeline opportunities and
the target indications for which they are being developed:

Therapeutic Product Candidates

Ophthalmology

LBI-001- Retinal Vein Occlusion (“RVO”)

RVO is a chronic
condition of the eye in which small blood clots form in the retinal veins. When this occurs, there is hemorrhage of blood from the blocked
vessels into the surrounding retinal tissue leading to swelling (macular edema) and formation of new blood vessels (neovascularization).
RVO is broadly classified into two sub-types. Central retinal vein occlusion (“CRVO”) occurs when the blood clot forms in
the central retinal vein. Branch retinal vein occlusion (“BRVO”) is four to six times more prevalent than CRVO and occurs
when the occlusion forms in the smaller branch retinal veins. Left untreated, RVO typically leads to permanent blindness over
a period of years and represents the second leading cause of retinal blindness behind diabetic retinopathy with a global market of approximately
28 million. Current treatments include anti-vascular endothelial growth factor (“anti-VEGF”) drugs such as Eylea,
Lucentis and Avastin. To a lesser extent, an out-patient surgical procedure known as laser photocoagulation is used to seal off leaking
blood vessels and slow the growth